Immunotherapy plus chemotherapy for advanced lung cancer not only prolongs life but also improves its quality

A recent clinical trial showed that the drug combination of cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer when compared with placebo plus platinum chemotherapy. Now an analysis published by Wiley online in Cancer, a peer-reviewed journal of the American Cancer Society, indicates that cemiplimab plus platinum chemotherapy also affects quality of life compared to chemotherapy alone.

Leave A Comment

Your email address will not be published. Required fields are marked *